Back to Strategies
Full Throttle
CustomMassive growth which are trading at a fair price. Our full throttle approach focuses on businesses with explosive growth which are trading at a fair price relative to their expected future growth rate.
All criteria must pass
Revenue Growth (5Y) ≥ 15.0
Revenue Growth (1Y) ≥ 20.0
Debt/Equity 0.0 – 5.0
PEG Ratio 0.0 – 2.0
Matching Stocks (100)
Export CSV| Company | Score | Actions | ||
|---|---|---|---|---|
Travere Therapeutics, Inc.
TVTX
|
|
|
||
|
Revenue Growth (5Y)
38.9
(≥ 15.0)
Revenue Growth (1Y)
110.5
(≥ 20.0)
Debt/Equity
2.9
(0.0 – 5.0)
PEG Ratio
0.8
(0.0 – 2.0)
|
||||
XPeng Inc.
XPEV
|
|
|
||
|
Revenue Growth (5Y)
37.3
(≥ 15.0)
Revenue Growth (1Y)
82.6
(≥ 20.0)
Debt/Equity
1.2
(0.0 – 5.0)
PEG Ratio
1.0
(0.0 – 2.0)
|
||||
Tempus AI, Inc.
TEM
|
|
|
||
|
Revenue Growth (5Y)
49.0
(≥ 15.0)
Revenue Growth (1Y)
83.4
(≥ 20.0)
Debt/Equity
1.7
(0.0 – 5.0)
PEG Ratio
0.6
(0.0 – 2.0)
|
||||
Amprius Technologies, Inc.
AMPX
|
|
|
||
|
Revenue Growth (5Y)
126.5
(≥ 15.0)
Revenue Growth (1Y)
202.1
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
1.0
(0.0 – 2.0)
|
||||
Abivax S.A.
ABVX
|
|
|
||
|
Revenue Growth (5Y)
261.8
(≥ 15.0)
Revenue Growth (1Y)
133.5
(≥ 20.0)
Debt/Equity
2.4
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Liquidia Corporation
LQDA
|
|
|
||
|
Revenue Growth (5Y)
87.3
(≥ 15.0)
Revenue Growth (1Y)
1031.2
(≥ 20.0)
Debt/Equity
4.4
(0.0 – 5.0)
PEG Ratio
0.8
(0.0 – 2.0)
|
||||
Tarsus Pharmaceuticals, Inc.
TARS
|
|
|
||
|
Revenue Growth (5Y)
67.7
(≥ 15.0)
Revenue Growth (1Y)
146.7
(≥ 20.0)
Debt/Equity
0.3
(0.0 – 5.0)
PEG Ratio
1.1
(0.0 – 2.0)
|
||||
AnaptysBio, Inc.
ANAB
|
|
|
||
|
Revenue Growth (5Y)
38.8
(≥ 15.0)
Revenue Growth (1Y)
157.0
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
1.1
(0.0 – 2.0)
|
||||
Rhythm Pharmaceuticals, Inc.
RYTM
|
|
|
||
|
Revenue Growth (5Y)
178.5
(≥ 15.0)
Revenue Growth (1Y)
45.8
(≥ 20.0)
Debt/Equity
1.8
(0.0 – 5.0)
PEG Ratio
1.2
(0.0 – 2.0)
|
||||
JBT Marel Corporation
JBTM
|
|
|
||
|
Revenue Growth (5Y)
28.3
(≥ 15.0)
Revenue Growth (1Y)
121.3
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
1.1
(0.0 – 2.0)
|
||||
WELL Health Technologies Corp.
WHTCF
|
|
|
||
|
Revenue Growth (5Y)
46.7
(≥ 15.0)
Revenue Growth (1Y)
52.1
(≥ 20.0)
Debt/Equity
0.8
(0.0 – 5.0)
PEG Ratio
1.1
(0.0 – 2.0)
|
||||
MDA Space Ltd
MDA
|
|
|
||
|
Revenue Growth (5Y)
33.3
(≥ 15.0)
Revenue Growth (1Y)
58.5
(≥ 20.0)
Debt/Equity
0.3
(0.0 – 5.0)
PEG Ratio
1.1
(0.0 – 2.0)
|
||||
argenx SE
ARGX
|
|
|
||
|
Revenue Growth (5Y)
70.1
(≥ 15.0)
Revenue Growth (1Y)
90.1
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
0.8
(0.0 – 2.0)
|
||||
Cronos Group Inc.
CRON
|
|
|
||
|
Revenue Growth (5Y)
31.6
(≥ 15.0)
Revenue Growth (1Y)
64.4
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
0.9
(0.0 – 2.0)
|
||||
AST SpaceMobile, Inc.
ASTS
|
|
|
||
|
Revenue Growth (5Y)
54.6
(≥ 15.0)
Revenue Growth (1Y)
1505.2
(≥ 20.0)
Debt/Equity
1.2
(0.0 – 5.0)
PEG Ratio
1.8
(0.0 – 2.0)
|
||||
Dutch Bros Inc.
BROS
|
|
|
||
|
Revenue Growth (5Y)
34.7
(≥ 15.0)
Revenue Growth (1Y)
27.9
(≥ 20.0)
Debt/Equity
1.6
(0.0 – 5.0)
PEG Ratio
0.9
(0.0 – 2.0)
|
||||
Construction Partners, Inc.
ROAD
|
|
|
||
|
Revenue Growth (5Y)
32.6
(≥ 15.0)
Revenue Growth (1Y)
54.2
(≥ 20.0)
Debt/Equity
1.9
(0.0 – 5.0)
PEG Ratio
1.8
(0.0 – 2.0)
|
||||
Lucid Group, Inc.
LCID
|
|
|
||
|
Revenue Growth (5Y)
165.8
(≥ 15.0)
Revenue Growth (1Y)
67.6
(≥ 20.0)
Debt/Equity
1.2
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
Geron Corporation
GERN
|
|
|
||
|
Revenue Growth (5Y)
239.0
(≥ 15.0)
Revenue Growth (1Y)
138.8
(≥ 20.0)
Debt/Equity
1.1
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
Palantir Technologies Inc.
PLTR
|
|
|
||
|
Revenue Growth (5Y)
30.5
(≥ 15.0)
Revenue Growth (1Y)
56.2
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
1.1
(0.0 – 2.0)
|
||||
Jiangsu Expressway Company Limited
JEXYY
|
|
|
||
|
Revenue Growth (5Y)
30.4
(≥ 15.0)
Revenue Growth (1Y)
52.7
(≥ 20.0)
Debt/Equity
0.5
(0.0 – 5.0)
PEG Ratio
0.7
(0.0 – 2.0)
|
||||
Telecom Argentina S.A.
TEO
|
|
|
||
|
Revenue Growth (5Y)
37.7
(≥ 15.0)
Revenue Growth (1Y)
123.9
(≥ 20.0)
Debt/Equity
0.6
(0.0 – 5.0)
PEG Ratio
0.3
(0.0 – 2.0)
|
||||
FTAI Infrastructure Inc.
FIP
|
|
|
||
|
Revenue Growth (5Y)
43.0
(≥ 15.0)
Revenue Growth (1Y)
51.6
(≥ 20.0)
Debt/Equity
3.5
(0.0 – 5.0)
PEG Ratio
0.3
(0.0 – 2.0)
|
||||
NVIDIA Corporation
NVDA
|
|
|
||
|
Revenue Growth (5Y)
68.3
(≥ 15.0)
Revenue Growth (1Y)
65.5
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
0.6
(0.0 – 2.0)
|
||||
Viridian Therapeutics, Inc.
VRDN
|
|
|
||
|
Revenue Growth (5Y)
121.1
(≥ 15.0)
Revenue Growth (1Y)
23359.9
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
0.5
(0.0 – 2.0)
|
||||
Nutex Health, Inc.
NUTX
|
|
|
||
|
Revenue Growth (5Y)
27.5
(≥ 15.0)
Revenue Growth (1Y)
82.4
(≥ 20.0)
Debt/Equity
1.1
(0.0 – 5.0)
PEG Ratio
1.8
(0.0 – 2.0)
|
||||
CI&T Inc
CINT
|
|
|
||
|
Revenue Growth (5Y)
79.4
(≥ 15.0)
Revenue Growth (1Y)
511.0
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
0.3
(0.0 – 2.0)
|
||||
TKO Group Holdings, Inc.
TKO
|
|
|
||
|
Revenue Growth (5Y)
44.2
(≥ 15.0)
Revenue Growth (1Y)
68.9
(≥ 20.0)
Debt/Equity
1.1
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
First Advantage Corporation
FA
|
|
|
||
|
Revenue Growth (5Y)
21.9
(≥ 15.0)
Revenue Growth (1Y)
83.0
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
1.0
(0.0 – 2.0)
|
||||
IDEAYA Biosciences, Inc.
IDYA
|
|
|
||
|
Revenue Growth (5Y)
67.3
(≥ 15.0)
Revenue Growth (1Y)
3024.4
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
0.4
(0.0 – 2.0)
|
||||
Clearwater Analytics Holdings, Inc.
CWAN
|
|
|
||
|
Revenue Growth (5Y)
30.5
(≥ 15.0)
Revenue Growth (1Y)
61.9
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
1.6
(0.0 – 2.0)
|
||||
Evolv Technologies Holdings, Inc.
EVLV
|
|
|
||
|
Revenue Growth (5Y)
58.0
(≥ 15.0)
Revenue Growth (1Y)
40.5
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
0.9
(0.0 – 2.0)
|
||||
Gruma, S.A.B. de C.V.
GPAGF
|
|
|
||
|
Revenue Growth (5Y)
127.0
(≥ 15.0)
Revenue Growth (1Y)
1784.8
(≥ 20.0)
Debt/Equity
1.0
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
Beam Therapeutics Inc.
BEAM
|
|
|
||
|
Revenue Growth (5Y)
28.1
(≥ 15.0)
Revenue Growth (1Y)
120.0
(≥ 20.0)
Debt/Equity
0.2
(0.0 – 5.0)
PEG Ratio
0.4
(0.0 – 2.0)
|
||||
Satellogic Inc.
SATL
|
|
|
||
|
Revenue Growth (5Y)
42.9
(≥ 15.0)
Revenue Growth (1Y)
37.6
(≥ 20.0)
Debt/Equity
1.1
(0.0 – 5.0)
PEG Ratio
0.6
(0.0 – 2.0)
|
||||
Atour Lifestyle Holdings Limited
ATAT
|
|
|
||
|
Revenue Growth (5Y)
45.6
(≥ 15.0)
Revenue Growth (1Y)
31.3
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
1.0
(0.0 – 2.0)
|
||||
Cadeler A/S
CDLR
|
|
|
||
|
Revenue Growth (5Y)
89.0
(≥ 15.0)
Revenue Growth (1Y)
129.0
(≥ 20.0)
Debt/Equity
0.5
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Aker ASA
AKAAF
|
|
|
||
|
Revenue Growth (5Y)
29.3
(≥ 15.0)
Revenue Growth (1Y)
82.0
(≥ 20.0)
Debt/Equity
0.7
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
Innovative Aerosystems, Inc.
ISSC
|
|
|
||
|
Revenue Growth (5Y)
38.3
(≥ 15.0)
Revenue Growth (1Y)
78.6
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Xvivo Perfusion AB (publ)
XVIPY
|
|
|
||
|
Revenue Growth (5Y)
46.2
(≥ 15.0)
Revenue Growth (1Y)
37.6
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
1.1
(0.0 – 2.0)
|
||||
Grupo Gigante, S. A. B. de C. V.
GPGNF
|
|
|
||
|
Revenue Growth (5Y)
125.8
(≥ 15.0)
Revenue Growth (1Y)
2030.3
(≥ 20.0)
Debt/Equity
0.6
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
Exchange Income Corporation
EIFZF
|
|
|
||
|
Revenue Growth (5Y)
23.4
(≥ 15.0)
Revenue Growth (1Y)
23.1
(≥ 20.0)
Debt/Equity
1.5
(0.0 – 5.0)
PEG Ratio
1.0
(0.0 – 2.0)
|
||||
Eli Lilly and Company
LLY
|
|
|
||
|
Revenue Growth (5Y)
23.2
(≥ 15.0)
Revenue Growth (1Y)
44.7
(≥ 20.0)
Debt/Equity
1.6
(0.0 – 5.0)
PEG Ratio
0.5
(0.0 – 2.0)
|
||||
TG Therapeutics, Inc.
TGTX
|
|
|
||
|
Revenue Growth (5Y)
209.8
(≥ 15.0)
Revenue Growth (1Y)
87.3
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
TUI AG
TUIFF
|
|
|
||
|
Revenue Growth (5Y)
56.5
(≥ 15.0)
Revenue Growth (1Y)
22.5
(≥ 20.0)
Debt/Equity
2.5
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Lexicon Pharmaceuticals, Inc.
LXRX
|
|
|
||
|
Revenue Growth (5Y)
259.6
(≥ 15.0)
Revenue Growth (1Y)
60.2
(≥ 20.0)
Debt/Equity
0.6
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Zymeworks Inc.
ZYME
|
|
|
||
|
Revenue Growth (5Y)
41.2
(≥ 15.0)
Revenue Growth (1Y)
38.9
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
0.7
(0.0 – 2.0)
|
||||
Applied Optoelectronics, Inc.
AAOI
|
|
|
||
|
Revenue Growth (5Y)
21.2
(≥ 15.0)
Revenue Growth (1Y)
82.8
(≥ 20.0)
Debt/Equity
0.2
(0.0 – 5.0)
PEG Ratio
0.6
(0.0 – 2.0)
|
||||
Türk Telekomünikasyon Anonim Sirketi
TRKNY
|
|
|
||
|
Revenue Growth (5Y)
66.4
(≥ 15.0)
Revenue Growth (1Y)
62.6
(≥ 20.0)
Debt/Equity
0.6
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
4DMedical Limited
FDMDF
|
|
|
||
|
Revenue Growth (5Y)
127.9
(≥ 15.0)
Revenue Growth (1Y)
91.9
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Ouster, Inc.
OUST
|
|
|
||
|
Revenue Growth (5Y)
49.9
(≥ 15.0)
Revenue Growth (1Y)
52.5
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
0.4
(0.0 – 2.0)
|
||||
EVgo, Inc.
EVGO
|
|
|
||
|
Revenue Growth (5Y)
103.9
(≥ 15.0)
Revenue Growth (1Y)
49.6
(≥ 20.0)
Debt/Equity
0.3
(0.0 – 5.0)
PEG Ratio
0.4
(0.0 – 2.0)
|
||||
Koç Holding A.S.
KHOLY
|
|
|
||
|
Revenue Growth (5Y)
71.4
(≥ 15.0)
Revenue Growth (1Y)
29.1
(≥ 20.0)
Debt/Equity
2.2
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
Delivery Hero SE
DELHY
|
|
|
||
|
Revenue Growth (5Y)
49.3
(≥ 15.0)
Revenue Growth (1Y)
23.7
(≥ 20.0)
Debt/Equity
2.2
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Paymentus Holdings, Inc.
PAY
|
|
|
||
|
Revenue Growth (5Y)
31.9
(≥ 15.0)
Revenue Growth (1Y)
37.3
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
1.3
(0.0 – 2.0)
|
||||
Vital Farms, Inc.
VITL
|
|
|
||
|
Revenue Growth (5Y)
30.6
(≥ 15.0)
Revenue Growth (1Y)
25.3
(≥ 20.0)
Debt/Equity
0.2
(0.0 – 5.0)
PEG Ratio
1.1
(0.0 – 2.0)
|
||||
Cal-Maine Foods, Inc.
CALM
|
|
|
||
|
Revenue Growth (5Y)
33.3
(≥ 15.0)
Revenue Growth (1Y)
83.2
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
Amphenol Corporation
APH
|
|
|
||
|
Revenue Growth (5Y)
20.7
(≥ 15.0)
Revenue Growth (1Y)
51.7
(≥ 20.0)
Debt/Equity
1.2
(0.0 – 5.0)
PEG Ratio
0.5
(0.0 – 2.0)
|
||||
Smurfit Westrock Plc
SW
|
|
|
||
|
Revenue Growth (5Y)
28.2
(≥ 15.0)
Revenue Growth (1Y)
38.8
(≥ 20.0)
Debt/Equity
0.7
(0.0 – 5.0)
PEG Ratio
0.5
(0.0 – 2.0)
|
||||
CBIZ, Inc.
CBZ
|
|
|
||
|
Revenue Growth (5Y)
25.7
(≥ 15.0)
Revenue Growth (1Y)
52.1
(≥ 20.0)
Debt/Equity
1.0
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
Sanrio Company, Ltd.
SNROF
|
|
|
||
|
Revenue Growth (5Y)
37.1
(≥ 15.0)
Revenue Growth (1Y)
44.9
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
0.3
(0.0 – 2.0)
|
||||
Ceres Power Holdings plc
CPWHF
|
|
|
||
|
Revenue Growth (5Y)
25.2
(≥ 15.0)
Revenue Growth (1Y)
132.4
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
Adaptive Biotechnologies Corporation
ADPT
|
|
|
||
|
Revenue Growth (5Y)
15.7
(≥ 15.0)
Revenue Growth (1Y)
54.8
(≥ 20.0)
Debt/Equity
1.3
(0.0 – 5.0)
PEG Ratio
0.6
(0.0 – 2.0)
|
||||
PDD Holdings Inc.
PDD
|
|
|
||
|
Revenue Growth (5Y)
60.4
(≥ 15.0)
Revenue Growth (1Y)
59.0
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Arçelik Anonim Sirketi
ACKAY
|
|
|
||
|
Revenue Growth (5Y)
69.9
(≥ 15.0)
Revenue Growth (1Y)
32.7
(≥ 20.0)
Debt/Equity
3.5
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
Enka Insaat ve Sanayi A.S.
EKIVF
|
|
|
||
|
Revenue Growth (5Y)
57.0
(≥ 15.0)
Revenue Growth (1Y)
55.7
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
Japan Airport Terminal Co., Ltd.
JTTRY
|
|
|
||
|
Revenue Growth (5Y)
50.5
(≥ 15.0)
Revenue Growth (1Y)
24.1
(≥ 20.0)
Debt/Equity
1.1
(0.0 – 5.0)
PEG Ratio
0.3
(0.0 – 2.0)
|
||||
Relay Therapeutics, Inc.
RLAY
|
|
|
||
|
Revenue Growth (5Y)
50.1
(≥ 15.0)
Revenue Growth (1Y)
53.4
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
Wise plc
WIZEY
|
|
|
||
|
Revenue Growth (5Y)
43.9
(≥ 15.0)
Revenue Growth (1Y)
27.9
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
1.4
(0.0 – 2.0)
|
||||
Super Micro Computer, Inc.
SMCI
|
|
|
||
|
Revenue Growth (5Y)
57.7
(≥ 15.0)
Revenue Growth (1Y)
46.6
(≥ 20.0)
Debt/Equity
0.8
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
Zinzino AB (publ)
ZNZNF
|
|
|
||
|
Revenue Growth (5Y)
24.7
(≥ 15.0)
Revenue Growth (1Y)
72.6
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
Ford Otomotiv Sanayi A.S.
FOVSY
|
|
|
||
|
Revenue Growth (5Y)
84.9
(≥ 15.0)
Revenue Growth (1Y)
39.6
(≥ 20.0)
Debt/Equity
1.1
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
Técnicas Reunidas, S.A.
TNISF
|
|
|
||
|
Revenue Growth (5Y)
23.2
(≥ 15.0)
Revenue Growth (1Y)
45.2
(≥ 20.0)
Debt/Equity
1.6
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Nova Ltd.
NVMI
|
|
|
||
|
Revenue Growth (5Y)
20.6
(≥ 15.0)
Revenue Growth (1Y)
31.0
(≥ 20.0)
Debt/Equity
0.7
(0.0 – 5.0)
PEG Ratio
1.0
(0.0 – 2.0)
|
||||
TransMedics Group, Inc.
TMDX
|
|
|
||
|
Revenue Growth (5Y)
111.5
(≥ 15.0)
Revenue Growth (1Y)
37.1
(≥ 20.0)
Debt/Equity
1.0
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Advantest Corporation
ADTTF
|
|
|
||
|
Revenue Growth (5Y)
25.7
(≥ 15.0)
Revenue Growth (1Y)
60.3
(≥ 20.0)
Debt/Equity
0.2
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
Luckin Coffee Inc.
LKNCY
|
|
|
||
|
Revenue Growth (5Y)
57.1
(≥ 15.0)
Revenue Growth (1Y)
37.1
(≥ 20.0)
Debt/Equity
0.7
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
Camurus AB (publ)
CAMRF
|
|
|
||
|
Revenue Growth (5Y)
39.4
(≥ 15.0)
Revenue Growth (1Y)
21.3
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
0.7
(0.0 – 2.0)
|
||||
Badger Infrastructure Solutions Ltd.
BDGIF
|
|
|
||
|
Revenue Growth (5Y)
19.3
(≥ 15.0)
Revenue Growth (1Y)
55.9
(≥ 20.0)
Debt/Equity
0.9
(0.0 – 5.0)
PEG Ratio
0.4
(0.0 – 2.0)
|
||||
Dave Inc.
DAVE
|
|
|
||
|
Revenue Growth (5Y)
35.2
(≥ 15.0)
Revenue Growth (1Y)
47.5
(≥ 20.0)
Debt/Equity
0.2
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Immunocore Holdings plc
IMCR
|
|
|
||
|
Revenue Growth (5Y)
69.0
(≥ 15.0)
Revenue Growth (1Y)
20.1
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
1.4
(0.0 – 2.0)
|
||||
Comfort Systems USA, Inc.
FIX
|
|
|
||
|
Revenue Growth (5Y)
31.2
(≥ 15.0)
Revenue Growth (1Y)
29.5
(≥ 20.0)
Debt/Equity
0.3
(0.0 – 5.0)
PEG Ratio
0.3
(0.0 – 2.0)
|
||||
Confluent, Inc.
CFLT
|
|
|
||
|
Revenue Growth (5Y)
31.7
(≥ 15.0)
Revenue Growth (1Y)
21.1
(≥ 20.0)
Debt/Equity
1.0
(0.0 – 5.0)
PEG Ratio
1.8
(0.0 – 2.0)
|
||||
The Pennant Group, Inc.
PNTG
|
|
|
||
|
Revenue Growth (5Y)
21.2
(≥ 15.0)
Revenue Growth (1Y)
36.3
(≥ 20.0)
Debt/Equity
1.4
(0.0 – 5.0)
PEG Ratio
1.7
(0.0 – 2.0)
|
||||
Taiwan Semiconductor Manufacturing Company Limited
TSM
|
|
|
||
|
Revenue Growth (5Y)
24.8
(≥ 15.0)
Revenue Growth (1Y)
33.0
(≥ 20.0)
Debt/Equity
0.2
(0.0 – 5.0)
PEG Ratio
0.6
(0.0 – 2.0)
|
||||
Raksul Inc.
RKSLF
|
|
|
||
|
Revenue Growth (5Y)
19.6
(≥ 15.0)
Revenue Growth (1Y)
21.2
(≥ 20.0)
Debt/Equity
1.1
(0.0 – 5.0)
PEG Ratio
1.2
(0.0 – 2.0)
|
||||
Galapagos N.V.
GLPG
|
|
|
||
|
Revenue Growth (5Y)
23.1
(≥ 15.0)
Revenue Growth (1Y)
303.5
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
0.0
(0.0 – 2.0)
|
||||
Neurocrine Biosciences, Inc.
NBIX
|
|
|
||
|
Revenue Growth (5Y)
26.0
(≥ 15.0)
Revenue Growth (1Y)
21.5
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
0.7
(0.0 – 2.0)
|
||||
monday.com Ltd.
MNDY
|
|
|
||
|
Revenue Growth (5Y)
41.4
(≥ 15.0)
Revenue Growth (1Y)
26.8
(≥ 20.0)
Debt/Equity
0.3
(0.0 – 5.0)
PEG Ratio
0.3
(0.0 – 2.0)
|
||||
Flywire Corporation
FLYW
|
|
|
||
|
Revenue Growth (5Y)
32.7
(≥ 15.0)
Revenue Growth (1Y)
26.6
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
0.3
(0.0 – 2.0)
|
||||
Duolingo, Inc.
DUOL
|
|
|
||
|
Revenue Growth (5Y)
42.6
(≥ 15.0)
Revenue Growth (1Y)
38.7
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Twist Bioscience Corporation
TWST
|
|
|
||
|
Revenue Growth (5Y)
29.9
(≥ 15.0)
Revenue Growth (1Y)
20.3
(≥ 20.0)
Debt/Equity
0.3
(0.0 – 5.0)
PEG Ratio
0.3
(0.0 – 2.0)
|
||||
DoorDash, Inc.
DASH
|
|
|
||
|
Revenue Growth (5Y)
29.4
(≥ 15.0)
Revenue Growth (1Y)
27.9
(≥ 20.0)
Debt/Equity
0.4
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
Kraken Robotics Inc.
KRKNF
|
|
|
||
|
Revenue Growth (5Y)
65.1
(≥ 15.0)
Revenue Growth (1Y)
31.2
(≥ 20.0)
Debt/Equity
0.2
(0.0 – 5.0)
PEG Ratio
0.1
(0.0 – 2.0)
|
||||
Saab AB (publ)
SAABY
|
|
|
||
|
Revenue Growth (5Y)
19.2
(≥ 15.0)
Revenue Growth (1Y)
24.2
(≥ 20.0)
Debt/Equity
0.3
(0.0 – 5.0)
PEG Ratio
1.1
(0.0 – 2.0)
|
||||
Redcare Pharmacy N.V.
SHPPF
|
|
|
||
|
Revenue Growth (5Y)
29.0
(≥ 15.0)
Revenue Growth (1Y)
24.0
(≥ 20.0)
Debt/Equity
0.9
(0.0 – 5.0)
PEG Ratio
2.0
(0.0 – 2.0)
|
||||
Harmony Biosciences Holdings, Inc.
HRMY
|
|
|
||
|
Revenue Growth (5Y)
29.9
(≥ 15.0)
Revenue Growth (1Y)
21.5
(≥ 20.0)
Debt/Equity
0.3
(0.0 – 5.0)
PEG Ratio
1.7
(0.0 – 2.0)
|
||||
SI-BONE, Inc.
SIBN
|
|
|
||
|
Revenue Growth (5Y)
22.2
(≥ 15.0)
Revenue Growth (1Y)
20.2
(≥ 20.0)
Debt/Equity
0.0
(0.0 – 5.0)
PEG Ratio
1.1
(0.0 – 2.0)
|
||||
Recursion Pharmaceuticals, Inc.
RXRX
|
|
|
||
|
Revenue Growth (5Y)
65.3
(≥ 15.0)
Revenue Growth (1Y)
26.9
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
0.2
(0.0 – 2.0)
|
||||
BayCurrent Consulting, Inc.
BYCRF
|
|
|
||
|
Revenue Growth (5Y)
28.3
(≥ 15.0)
Revenue Growth (1Y)
23.6
(≥ 20.0)
Debt/Equity
0.1
(0.0 – 5.0)
PEG Ratio
1.7
(0.0 – 2.0)
|
||||